RB1 and neuroendocrine carcinoma: Regarding potential biomarkers, the benefit of platinum-based treatment for pancreatic NEN G3 has been reported to depend on KRAS mutations and loss of RB1 (Hijioka et al. 2017) and studies on NEC have associated microsatellite instability (MSI) with improved prognosis (La Rosa et al. 2012, Sahnane et al. 2015).